Literature DB >> 28579679

Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy.

Andrew Marsala1, Edward W Lee1, Siddharth A Padia1.   

Abstract

Metastatic colorectal cancer represents the most common liver malignancy, and imparts a very poor prognosis for those who develop this disease. Unlike primary liver tumors such as hepatocellular carcinoma, which largely develops in patients with underlying cirrhosis, most metastatic liver tumor patients have normal underlying liver function. Owing to this, most will succumb to tumoral replacement of the liver rather than from underlying liver dysfunction. Radioembolization represents a treatment modality that can be used in multiple fashions to treat one or both lobes of the liver. Techniques depend on whether the procedure is used as first-line, second/third-line, or as salvage therapy. Outcomes and complications of radioembolization are presented in this article, as well as background information on colorectal cancer and systemic therapies.

Entities:  

Keywords:  chemotherapy; colorectal cancer; interventional radiology; radioembolization; transarterial therapy

Year:  2017        PMID: 28579679      PMCID: PMC5453784          DOI: 10.1055/s-0037-1602711

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  36 in total

1.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.

Authors:  Lourens Bester; Baerbel Meteling; Nicholas Pocock; Nick Pavlakis; Terence C Chua; Akshat Saxena; David L Morris
Journal:  J Vasc Interv Radiol       Date:  2011-11-12       Impact factor: 3.464

Review 3.  The continuum of care: a paradigm for the management of metastatic colorectal cancer.

Authors:  Richard M Goldberg; Mace L Rothenberg; Eric Van Cutsem; Al B Benson; Charles D Blanke; Robert B Diasio; Axel Grothey; Heinz-Josef Lenz; Neal J Meropol; Ramesh K Ramanathan; Carlos H Roberto Becerra; Rita Wickham; Delma Armstrong; Carol Viele
Journal:  Oncologist       Date:  2007-01

4.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

Review 5.  Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions.

Authors:  Siddharth A Padia; Robert J Lewandowski; Guy E Johnson; Daniel Y Sze; Thomas J Ward; Ron C Gaba; Mark O Baerlocher; Vanessa L Gates; Ahsun Riaz; Daniel B Brown; Nasir H Siddiqi; T Gregory Walker; James E Silberzweig; Jason W Mitchell; Boris Nikolic; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2016-11-09       Impact factor: 3.464

6.  Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Authors:  Lieke H J Simkens; Harm van Tinteren; Anne May; Albert J ten Tije; Geert-Jan M Creemers; Olaf J L Loosveld; Felix E de Jongh; Frans L G Erdkamp; Zoran Erjavec; Adelheid M E van der Torren; Jolien Tol; Hans J J Braun; Peter Nieboer; Jacobus J M van der Hoeven; Janny G Haasjes; Rob L H Jansen; Jaap Wals; Annemieke Cats; Veerle A Derleyn; Aafke H Honkoop; Linda Mol; Cornelis J A Punt; Miriam Koopman
Journal:  Lancet       Date:  2015-04-07       Impact factor: 79.321

Review 7.  Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?

Authors:  Bippan Singh Sangha; Halla Nimeiri; Ryan Hickey; Riad Salem; Robert J Lewandowski
Journal:  Curr Treat Options Oncol       Date:  2016-06

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.

Authors:  F Loupakis; C Cremolini; L Salvatore; G Masi; E Sensi; M Schirripa; A Michelucci; E Pfanner; I Brunetti; C Lupi; C Antoniotti; F Bergamo; S Lonardi; V Zagonel; P Simi; G Fontanini; A Falcone
Journal:  Eur J Cancer       Date:  2013-10-15       Impact factor: 9.162

View more
  1 in total

1.  TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial.

Authors:  Nikhil Chauhan; Mary F Mulcahy; Riad Salem; Al B Benson Iii; Eveline Boucher; Janet Bukovcan; David Cosgrove; Chantal Laframboise; Robert J Lewandowski; Fayaz Master; Bassel El-Rayes; Jonathan R Strosberg; Daniel Y Sze; Ricky A Sharma
Journal:  JMIR Res Protoc       Date:  2019-01-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.